Depigmentation Therapies for Vitiligo.
The general goals of medical management of vitiligo are to repigment vitiliginous areas of skin and to stabilize the progression of depigmentation. However, for some patients with vitiligo affecting extensive body surface areas who are unresponsive to repigmentation therapies, depigmentation of the remaining normal skin may be a better choice. Candidates for depigmentation therapy should be carefully screened and patient education is essential. Permanent topical therapies used for depigmentation include monobenzyl ether of hydroquinone, 4-methoxyphenol, and 88% phenol. Physical modalities, such as cryotherapy and lasers, are also being used successfully.
Vitiligo & Pigmentation Institute of Southern California, 5670 Wilshire Boulevard #650, Los Angeles, CA 90036, USA; Division of Dermatology, David Geffen School of Medicine, University of California, Los Angeles, 10833 Le Conte Avenue, Los Angeles, CA 90095, USA. Electronic address: pegrimesmd@aol.com.
Pearl E
PE
Grimes
Vitiligo & Pigmentation Institute of Southern California, 5670 Wilshire Boulevard #650, Los Angeles, CA 90036, USA.
Rama
R
Nashawati
D000276:Adjuvants, Immunologic / Q000627:therapeutic use*; D000634:Aminoquinolines / Q000627:therapeutic use; D000840:Anisoles / Q000627:therapeutic use*; D001830:Body Surface Area; D017679:Cryotherapy; D003521:Cyclopropanes / Q000627:therapeutic use; D006801:Humans; D006873:Hydroquinones / Q000627:therapeutic use*; D000068877:Imatinib Mesylate / Q000627:therapeutic use; D000077271:Imiquimod; D028022:Low-Level Light Therapy; D018579:Patient Selection; D019800:Phenol / Q000627:therapeutic use*; D047428:Protein Kinase Inhibitors / Q000627:therapeutic use*; D012720:Severity of Illness Index; D062327:Skin Lightening Preparations / Q000627:therapeutic use*; D014820:Vitiligo / Q000628:therapy*
D000276:Adjuvants, Immunologic; D000634:Aminoquinolines; D000840:Anisoles; D003521:Cyclopropanes; D006873:Hydroquinones; D047428:Protein Kinase Inhibitors; D062327:Skin Lightening Preparations; D019800:Phenol; C009760:mequinol; D000068877:Imatinib Mesylate; C006429:monobenzone; C029402:diphenylcyclopropenone; D000077271:Imiquimod
4-Methoxyphenol; Depigmentation; Disorders of appearance; MBEH; Mequinol; Monobenzyl ether of hydroquinone; Pigmentary disorders; Vitiligo